Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

464.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
54 55 Next >
3 Growth Stocks to Buy Right Now Without Any Hesitation
Investors shouldn't have to deliberate for too long about these great stocks. 
Via The Motley Fool
4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 15% decline in the Nasdaq Composite is a red-carpet opportunity for investors to snag high-quality growth stocks at a discount. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before. 
Via Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
What 10 Analyst Ratings Have To Say About Vertex Pharmaceuticals
Via Benzinga
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Exploring NASDAQ:VRTX's quality characteristics.
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
3 Biotech Stocks That Are Betting on the Future of Gene Editing
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex shares look cheap today considering all the company has to offer. 
Via The Motley Fool
Why you can make Vertex Pharmaceuticals a buy on any pullback
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
Via MarketBeat
Exposures COVID-19
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
No biotech stock is worry-free. But investors shouldn't fret about these four issues for Vertex. 
Via The Motley Fool
Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus
The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments. 
Via Investor's Business Daily
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates. 
Via Benzinga
Topics Earnings
Exposures Financial
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Reports Third Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
Roku vaulted 50% to become Ark Innovation's top holding. 
Via Investor's Business Daily
US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields
The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
The meeting went almost as well as could be expected. 
Via The Motley Fool
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
The agency could soon approve a potential cure for sickle cell disease . 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
4x returns in just a decade is quite an attainable result for these companies. 
Via The Motley Fool
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
Via InvestorPlace
Exposures Product Safety
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.